Prestige Consumer Healthcare Inc. (NYSE:PBH) Receives Average Rating of “Hold” from Analysts

Prestige Consumer Healthcare Inc. (NYSE:PBH) has been given a consensus recommendation of “Hold” by the seven brokerages that are covering the firm, MarketBeat.com reports. Four equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. The average 12-month target price among analysts that have issued ratings on the stock in the last year is $80.60.

PBH has been the subject of a number of research reports. Weiss Ratings reissued a “hold (c)” rating on shares of Prestige Consumer Healthcare in a research report on Thursday, January 22nd. Zacks Research raised Prestige Consumer Healthcare from a “strong sell” rating to a “hold” rating in a research note on Monday, November 10th. Canaccord Genuity Group lowered their price target on Prestige Consumer Healthcare from $100.00 to $88.00 and set a “buy” rating for the company in a research note on Friday, November 7th. Oppenheimer cut their price objective on shares of Prestige Consumer Healthcare from $82.00 to $72.00 and set an “outperform” rating on the stock in a research report on Tuesday, October 21st. Finally, Jefferies Financial Group decreased their target price on shares of Prestige Consumer Healthcare from $70.00 to $66.00 and set a “hold” rating for the company in a research report on Friday, January 30th.

Prestige Consumer Healthcare News Roundup

Here are the key news stories impacting Prestige Consumer Healthcare this week:

• Positive Sentiment: Management highlighted progress restoring Clear Eyes supply and said availability is improving, which supports a rebound in that brand’s sales going forward. Prestige Consumer Healthcare narrows fiscal 2026 revenue outlook to $1.1B while advancing Clear Eyes supply recovery
• Positive Sentiment: The company narrowed and finalized its fiscal‑2026 revenue outlook to about $1.1 billion, which reduces uncertainty around full‑year expectations and may reassure investors. Prestige Consumer Healthcare Q3 revenue tops estimates, narrows guidance
• Neutral Sentiment: Management posted the full slide deck and call transcript; these provide detail on segment trends, margins and working‑capital dynamics for investors doing deeper diligence. Q3 2026 Earnings Call Transcript
• Negative Sentiment: Q3 results showed a small EPS miss: $1.14 reported vs. ~$1.16 consensus, and revenue of ~$283.4M was down roughly 2.4% year‑over‑year—factors that are short‑term headwinds for the stock. Prestige Consumer Healthcare (PBH) Q3 Earnings Lag Estimates
• Negative Sentiment: Fiscal‑2026 EPS guidance was set at 4.54 (company’s figure), essentially flat-to-slightly below some sell‑side consensus (~4.55), leaving limited upside in near‑term estimates. Press release: Third Quarter and Year-to-Date Fiscal 2026 Results

Insider Transactions at Prestige Consumer Healthcare

In other Prestige Consumer Healthcare news, VP Jeffrey Zerillo sold 719 shares of the stock in a transaction on Friday, November 28th. The shares were sold at an average price of $60.00, for a total transaction of $43,140.00. Following the transaction, the vice president directly owned 42,329 shares of the company’s stock, valued at $2,539,740. This represents a 1.67% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Corporate insiders own 1.40% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the stock. Caitong International Asset Management Co. Ltd boosted its position in Prestige Consumer Healthcare by 312.5% during the second quarter. Caitong International Asset Management Co. Ltd now owns 330 shares of the company’s stock worth $26,000 after purchasing an additional 250 shares during the period. Bayforest Capital Ltd acquired a new stake in shares of Prestige Consumer Healthcare in the fourth quarter worth $29,000. First Horizon Corp bought a new stake in shares of Prestige Consumer Healthcare during the 3rd quarter worth $32,000. Barrow Hanley Mewhinney & Strauss LLC grew its stake in Prestige Consumer Healthcare by 106.8% in the 3rd quarter. Barrow Hanley Mewhinney & Strauss LLC now owns 548 shares of the company’s stock valued at $34,000 after buying an additional 283 shares during the last quarter. Finally, Geneos Wealth Management Inc. raised its holdings in Prestige Consumer Healthcare by 92.8% in the 1st quarter. Geneos Wealth Management Inc. now owns 559 shares of the company’s stock worth $48,000 after acquiring an additional 269 shares during the period. Institutional investors and hedge funds own 99.95% of the company’s stock.

Prestige Consumer Healthcare Stock Performance

PBH stock opened at $66.48 on Friday. The firm has a 50 day simple moving average of $63.19 and a 200 day simple moving average of $64.06. Prestige Consumer Healthcare has a 52 week low of $57.25 and a 52 week high of $90.04. The stock has a market cap of $3.20 billion, a P/E ratio of 17.59, a P/E/G ratio of 2.06 and a beta of 0.43. The company has a debt-to-equity ratio of 0.58, a quick ratio of 2.51 and a current ratio of 3.11.

Prestige Consumer Healthcare (NYSE:PBH) last released its earnings results on Thursday, February 5th. The company reported $1.14 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.16 by ($0.02). The company had revenue of $283.44 million during the quarter, compared to analysts’ expectations of $286.93 million. Prestige Consumer Healthcare had a return on equity of 12.02% and a net margin of 16.90%.The firm’s quarterly revenue was down 2.4% compared to the same quarter last year. During the same quarter in the previous year, the company earned $1.22 EPS. Prestige Consumer Healthcare has set its FY 2026 guidance at 4.540-4.540 EPS. Research analysts anticipate that Prestige Consumer Healthcare will post 4.5 earnings per share for the current fiscal year.

Prestige Consumer Healthcare Company Profile

Prestige Consumer Healthcare, Inc is a leading manufacturer and marketer of branded over-the-counter (OTC) healthcare products. The company focuses on developing, acquiring and commercializing a diverse portfolio of non-prescription remedies designed to address common consumer health needs, including pain relief, cold and cough, digestive health, eye care, skin care and women’s health.

Key brands in Prestige’s portfolio include Clear Eyes (eye health), Carmex (lip care), Chloraseptic (sore throat relief), Dramamine (motion sickness), Rolaids (antacid), Monistat (women’s health), BC Powder (pain relief), Little Remedies (pediatric cold and gas relief) and TheraTears (dry eye therapy).